特此公告！ 网上集体接待日暨2024年度业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 为进一步加强与投资者的互动交流，青岛英派斯健康科技股份有限公司（以下简称"公司"）将参加由青 岛证监局指导，青岛市上市公司协会与深圳市全景网络有限公司联合举办的"2025年青岛辖区上市公司 投资者网上集体接待日暨2024年度业绩说明会活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站（http://rs.p5w.net）；或关注微信 公众号（名称：全景财经）；或下载全景路演APP，参与本次互动交流。活动时间为2025年5月12日 （周一）15:00-17:00。届时公司董事长、总经理刘洪涛先生，独立董事孟凡强先生，财务负责人梁春红 女士，副总经理、董事会秘书张瑞女士，保荐代表人张兴林先生将以在线交流形式就公司治理、发展战 略、经营状况和可持续发展等投资者关注的问题与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码： 002899 证券简称：英派斯 公告编号 ...

证券代码：002899 证券简称：英派斯 公告编号：2025-022 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，青岛英派斯健康科技股份有限公司（以 下简称"公司"）将参加由青岛证监局指导，青岛市上市公司协会与深圳市全 景网络有限公司联合举办的"2025 年青岛辖区上市公司投资者网上集体接待日 暨 2024 年度业绩说明会活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路演 APP，参与本次互动交流。活动时间为 2025 年 5 月 12 日（周一）15:00-17:00。 届时公司董事长、总经理刘洪涛先生，独立董事孟凡强先生，财务负责人梁春 红女士，副总经理、董事会秘书张瑞女士，保荐代表人张兴林先生将以在线交 流形式就公司治理、发展战略、经营状况和可持续发展等投资者关注的问题与 投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告！ 青岛英派斯健康科技股份有限公司 董事会 2025 年 ...

Summary of Key Points from the Conference Call Industry Overview - The conference call focuses on the **media industry** and highlights significant opportunities in **AI** and **AI glasses** for the second quarter and second half of 2025, particularly following positive guidance from President Xi Jinping regarding AI glasses, which may catalyze the industry [1][2] - The **gaming sector** is noted for its strong performance, with several companies exceeding market expectations in the first quarter of 2025 [2] Core Insights and Arguments - **AI and AI Glasses**: The media industry should pay attention to AI and AI glasses, with a projected market size of **4.71 billion** yuan by 2027, and **Inpaas** expected to generate over **90 million** yuan in net profit, contributing to a market capitalization increase of **2.8 billion** yuan [1][5] - **Film and Gaming Projects**: Anticipated summer releases include animated films like **"Three Kingdoms Starry Sky"** and **"Wang Wang Island,"** along with games such as **"One Ring"** and **"SLG 5,000 Years,"** which are expected to drive revenue for related companies [1][4] - **Fengjun Media**: Reported first-quarter revenue of **2.858 billion** yuan, a **4.7%** year-on-year increase, and a net profit of **1.135 billion** yuan, up **9.14%** year-on-year, with a dividend yield exceeding **6%** [1][8] - **Gaming Sector Performance**: The gaming sector reported a profit of **3.476 billion** yuan in Q1 2025, a **41.7%** increase year-on-year, with notable performances from companies like **Kying Network**, **Perfect World**, **ST Huayun**, and **Jibite** [1][11] Additional Important Insights - **Mergers and Acquisitions**: Fengjun Media's recent acquisition of **Xinchao** is expected to enhance overall efficiency and bargaining power, positively impacting future performance [1][9] - **Education Sector**: The education sector is highlighted for its strong domestic demand characteristics, with recommendations to focus on high-performance, high-dividend stocks like **Oriental Education**, which saw a **15%-35%** increase in spring enrollment [2][12] - **Doushen Education**: As the first AI+ education application stock in A-shares, its **AI class** product is expected to launch in Q2, potentially replacing online language courses and driving significant revenue growth [2][15][16] - **Market Dynamics**: The K12 education sector is advised to focus on AI-enabled education, with companies like **Doushen Education** and **Shengtong Co.** showing promise for future growth [2][14][17] This summary encapsulates the key points discussed in the conference call, providing insights into the media and gaming industries, as well as emerging opportunities in AI and education sectors.

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Views - The company reported a revenue of 1.21 billion yuan for 2024, representing a year-on-year increase of 35.6%, and a net profit of 109 million yuan, up 23.8% [2][3] - The company is focusing on both international market dynamics and expanding its domestic market presence, with significant growth potential in China's fitness equipment market [4] - The company is actively pursuing a smart transformation by integrating AI technology into its product offerings, which includes 28 series of fitness equipment [5] Summary by Sections Financial Performance - In 2024, the company achieved a revenue of 1.21 billion yuan, with a year-on-year growth of 35.6%, and a net profit of 109 million yuan, reflecting a growth of 23.8% [2][3] - For Q1 2025, the revenue was 291 million yuan, showing a year-on-year increase of 21.9%, with a net profit of 14 million yuan, up 2.19% [2] Business Growth - The traditional business segment is experiencing steady growth, with commercial products accounting for 87.7% of revenue and overseas sales making up 78.7% [3] - The company is enhancing its OEM/ODM product offerings and has successfully launched over 10 new products [3] Market Potential - The domestic fitness market is expected to grow significantly, with China's fitness penetration rate at 5.37% as of 2023, compared to higher rates in the US, UK, and Germany [4] - The company aims to mitigate risks associated with international markets by tapping into the vast potential of the domestic market [4] Strategic Initiatives - The company is deepening its application of AI technology to create smart fitness solutions, positioning itself for future growth in the AI glasses sector [5] - The report forecasts revenue growth for 2025-2027 to be 1.31 billion, 1.64 billion, and 1.89 billion yuan, respectively, with net profits projected at 103 million, 144 million, and 181 million yuan [6][8]

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company has shown strong revenue growth, achieving 1.214 billion yuan in 2024, a year-on-year increase of 35.6%, and a net profit of 109 million yuan, up 23.8% year-on-year [2][3] - The company is experiencing a transformation with a focus on its own brand, which is expected to continue driving high growth in 2025 [2] - The company’s profitability faced temporary pressure due to increased depreciation costs, but operational efficiency is expected to improve in the coming quarters [3] Summary by Sections Financial Performance - In 2024, the company achieved total revenue of 1.214 billion yuan, with a year-on-year growth rate of 35.6% [4] - The net profit attributable to the parent company for 2024 was 109 million yuan, reflecting a year-on-year increase of 23.8% [4] - For Q1 2025, the company reported revenue of 291 million yuan, a year-on-year increase of 21.9%, and a net profit of 14 million yuan, which is a slight increase of 2.2% year-on-year [3] Revenue Breakdown - In 2024, domestic sales generated 259 million yuan (up 7.5% year-on-year), while overseas sales reached 955 million yuan (up 45.9% year-on-year) [2] - The gross margin for domestic sales was 33.0% (up 5.4 percentage points), while for overseas sales it was 31.4% (down 2.0 percentage points) [2] Profitability and Cost Management - The gross margin for Q1 2025 was 25.4%, down 2.8 percentage points year-on-year, while the net profit margin was 4.9%, down 0.9 percentage points year-on-year [3] - The company maintained a strong cost control with a total expense ratio of 19.20% in Q1 2025, which is a decrease of 1.1 percentage points year-on-year [3] Future Projections - The company’s net profit is projected to reach 125 million yuan in 2025, 143 million yuan in 2026, and 164 million yuan in 2027, with corresponding P/E ratios of 23.76X, 20.76X, and 18.08X respectively [4]

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company has shown strong revenue growth, achieving 1.214 billion yuan in 2024, a year-on-year increase of 35.6%, and a net profit of 109 million yuan, up 23.8% year-on-year [2][3] - The company is experiencing a transformation with a focus on its own brand, which is expected to continue driving high growth in the coming years [2][3] - The company is managing costs effectively, with a decrease in expense ratios, which is expected to improve profitability as production efficiency increases [3] Summary by Sections Financial Performance - In 2024, the company achieved total revenue of 1.214 billion yuan, with a year-on-year growth rate of 35.6% [4] - The net profit attributable to the parent company was 109 million yuan, reflecting a year-on-year increase of 23.8% [4] - For Q1 2025, the company reported revenue of 291 million yuan, a year-on-year increase of 21.9%, and a net profit of 14 million yuan, up 2.2% year-on-year [2][3] Revenue Breakdown - Domestic sales reached 259 million yuan, growing by 7.5% year-on-year, while overseas sales were 955 million yuan, up 45.9% year-on-year [2] - The gross margin for domestic sales was 33.0%, while for overseas sales it was 31.4% [2] Profitability and Cost Management - The gross margin for Q1 2025 was 25.4%, down 2.8 percentage points year-on-year, while the net profit margin was 4.9%, down 0.9 percentage points year-on-year [3] - The company has maintained a strong control over expenses, with a total expense ratio of 19.20%, down 1.1 percentage points year-on-year [3] Future Projections - The company is projected to achieve net profits of 125 million yuan, 143 million yuan, and 164 million yuan for 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 23.76X, 20.76X, and 18.08X [4][3]

Core Viewpoint - The company, Qingdao Inpace Health Technology Co., Ltd., has announced the reappointment of Heshin Accounting Firm as its auditor for the year 2025, ensuring the continuity of its auditing services and compliance with regulatory requirements [9][10][19]. Financial Data - The first quarter report for the company has not been audited [8]. - The company has repurchased 1,256,700 shares, accounting for 0.85% of the total share capital as of the reporting period [5]. Shareholder Information - The company has confirmed that there are no changes in the major shareholders and their shareholding status compared to the previous period [6]. Audit Firm Information - Heshin Accounting Firm has been selected for reappointment, with an audit fee of 850,000 yuan and an internal control audit fee of 280,000 yuan, remaining the same as the previous year [10][17]. - The firm has a total of 45 partners and 254 registered accountants, with 139 of them having signed audit reports for securities services [11]. - The firm has not faced any criminal penalties or disciplinary actions in the last three years [13][15]. Audit Committee and Board Decisions - The audit committee has reviewed and approved the reappointment of Heshin Accounting Firm, emphasizing its qualifications and independence [18]. - The board of directors unanimously approved the proposal to reappoint the audit firm, which will be subject to shareholder approval [19].

2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 3.第一季度报告是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √否 ■ （二） 非经常性损益项目和金额 √适用 □不适用 单位：元 ■ 其他符合非经常性损益定义的损益项目的具体情况 □适用 √不适用 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》中列举的非经常性损益项目界 定为经常性损益项目的情况说明 □适用 √不适用 公司不存在将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》中列举的非经常性 损益项目界定为经常性损益的项目 ...

青岛英派斯健康科技股份有限公司 非经营性资金占用及其他关联资金往来情况的 专项说明 二〇二五年四月二十五日 | 目 | 录 | 页 | 码 | | --- | --- | --- | --- | | 一、非经营性资金占用及其他关联资金往来情况的专项说明 | | 1-2 | | | 二、非经营性资金占用及其他关联资金往来情况汇总表 | | 3 | | 和信专字（2025）第 000259 号 和信会计师事务所（特殊普通合伙） 青岛英派斯健康科技股份有限公司 非经营性资金占用及其他关联资金往来情况的 专项说明 和信专字（2025）第 000259 号 青岛英派斯健康科技股份有限公司全体股东： 我们接受委托，审计了青岛英派斯健康科技股份有限公司（以下简称"英派斯"）2024 年度财务报表，包括 2024 年 12 月 31 日的合并及公司资产负债表，2024 年度的合并及公 司利润表、合并及公司现金流量表、合并及公司所有者权益变动表以及相关财务报表附注， 并于 2025 年 4 月 25 日出具了和信审字（2025）第 000689 号标准无保留意见审计报告。 根据中国证券监督管理委员会等四部委联合发布的《上市公司 ...

青岛英派斯健康科技股份有限公司 青岛英派斯健康科技股份有限公司全体股东： 一、审计意见 二○二五年四月二十五日 青岛英派斯健康科技股份有限公司 报告正文 审 计 报 告 和信审字（2025）第 000689 号 审计报告 和信审字（2025）第 000689 号 | 目 录 | 页 码 | | --- | --- | | 一、审计报告 | 1-8 | | 二、已审财务报表及附注 | | | 1、合并及公司资产负债表 | 9-12 | | 2、合并及公司利润表 | 13-14 | | 3、合并及公司现金流量表 | 15-16 | | 4、合并及公司所有者权益变动表 | 17-20 | | 5、财务报表附注 | 21-122 | 和信会计师事务所（特殊普通合伙） 我们审计了青岛英派斯健康科技股份有限公司（以下简称"英派斯"、"公司"） 财务报表，包括 2024 年 12 月 31 日的合并及公司资产负债表，2024 年度的合并 及公司利润表、合并及公司现金流量表、合并及公司股东权益变动表以及相关财 务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制， 公允反映了英派斯 2024 年 1 ...